Boehringer Ingelheim Strengthens Immuno-oncology Portfolio with T3 Pharma Acquisition
Boehringer Ingelheim has confirmed the acquisition of T3 Pharmaceuticals AG, a Swiss clinical-stage biotech company thereby expanding its immuno-oncology portfolio.
Read more